Philogen is a fully integrated company active in the discovery, GMP production and clinical development of targeted therapeutics.

We have a leading position in the field of antibody-based therapeutics specific for markers of angiogenesis. At present we have four targeted immunocytokines in clinical development in oncology and in chronic inflammatory diseases.

In addition, we are developing small molecule radiotracers for the non-invasive detection of a variety of solid tumors.


By continuing to browse or by closing this window, you accept the use of cookies.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. By closing this banner or continuing to browse, you agree to the use of cookies.

I Accept Cookie Policy